Treatment Plan for a 16-Year-Old Female with Depression
This adolescent requires immediate comprehensive suicide risk assessment, followed by evidence-based psychotherapy as first-line treatment, with consideration of SSRI medication if symptoms are moderate-to-severe or if psychotherapy alone is insufficient. 1
Immediate Safety Assessment
- Directly ask about suicidal ideation using specific questions: "Have you ever thought about killing yourself or wished you were dead?" followed by "Have you ever done anything on purpose to hurt or kill yourself?" 2
- Place these questions in the middle or toward the end of depression symptom screening to maintain rapport 2
- If any positive response, immediately assess for specific plans, access to firearms, intent, and timeline 2
- Safety takes precedence over confidentiality—explain this to both patient and family at the outset 2
- Arrange immediate mental health evaluation if suicidal ideation is present, through psychiatric hospitalization, emergency department transfer, or same-day mental health appointment 3
- Develop a safety plan that includes restricting lethal means (especially firearms), engaging a concerned third party, and establishing emergency communication mechanisms 1
Diagnostic Confirmation and Severity Assessment
- Use PHQ-9 as the primary screening tool (sensitivity 89.5%, specificity 77.5% at cutoff ≥11) 4
- Screening alone does not establish diagnosis—conduct direct clinical interview using DSM-5 criteria to confirm major depressive disorder 4
- Assess for the core symptoms: depressed or irritable mood, anhedonia (loss of interest/pleasure), changes in sleep/appetite/energy, guilt/worthlessness, concentration difficulties, psychomotor changes, and suicidal thoughts 2
- Evaluate functional impairment across school, home, and peer relationships 1
- Screen for bipolar disorder risk before initiating any antidepressant, as treating unrecognized bipolar disorder with antidepressants alone may precipitate manic episodes 5
- Assess for comorbid conditions: anxiety disorders, substance use, trauma history, and psychotic symptoms 1, 4
- Obtain collateral information from parents when possible 4
Baseline Laboratory Testing
- Obtain thyroid function studies (TSH) to rule out thyroid-induced depressive symptoms 4
- Complete blood count, liver function tests, and metabolic panel before initiating any antidepressant medication 4
- These establish baseline values for monitoring treatment-related adverse effects 4
Treatment Algorithm Based on Severity
Mild Symptoms (PHQ-9: 1-7)
- Provide psychoeducation about depression and normal stress responses 4
- Ensure adequate coping skills and access to resources 4
- Schedule reassessment at future visits, particularly given her age and symptom profile 4
Moderate Symptoms (PHQ-9: 8-14)
- Initiate evidence-based psychotherapy as first-line treatment 1, 6
- Effective modalities include cognitive behavioral therapy (CBT), behavioral activation, interpersonal therapy, or problem-solving therapy (effect sizes 0.50-0.73) 4
- Consider referral to psychology or psychiatry for diagnostic evaluation and treatment initiation 4
- If psychotherapy alone is insufficient after 8 weeks, add SSRI medication 1
Moderate-to-Severe/Severe Symptoms (PHQ-9: 15-27)
- Immediate referral to psychology and/or psychiatry for diagnosis and treatment 4
- Initiate combination treatment with both psychotherapy and SSRI medication, as combination therapy is superior to either alone for severe depression 7
- Assess for risk of harm to self or others immediately—any endorsement of specific plans or intent requires emergency intervention 4
Pharmacotherapy Considerations (If Indicated)
SSRI Selection and Dosing
- Fluoxetine is FDA-approved for adolescent major depressive disorder and has the most evidence in this age group 5
- Alternative: Sertraline starting at 25 mg daily for one week, then increase to 50 mg daily 8
- For adolescents 13-17 years, sertraline can be initiated at 50 mg daily 8
- Maximum dose: 200 mg/day for both fluoxetine and sertraline, with dose changes no more frequently than weekly given 24-hour elimination half-life 8
Critical Safety Monitoring for SSRIs
- Black box warning: Increased risk of suicidal thoughts and behaviors in adolescents and young adults during first few months of treatment or with dose changes 8, 5
- Monitor biweekly or monthly until symptoms remit for: new or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, or mania 8, 5
- These symptoms may represent precursors to emerging suicidality 5
- Obtain laboratory tests before each medication adjustment and monitor for hyponatremia (especially concerning in adolescents), liver function changes, and metabolic effects 4
- Given this patient's prominent anhedonia, be aware that anhedonia predicts poorer recovery and longer time to remission with SSRI treatment 9
Medication Management
- Schedule follow-up within 48-72 hours of treatment initiation, then weekly initially 10
- After 8 weeks, if symptom reduction is poor despite good compliance, alter treatment course by adding psychotherapy, changing medication, or increasing dose 11
- Assess compliance, side effects, and satisfaction at each visit 11
Psychotherapy Implementation
- Cognitive behavioral therapy (CBT) is as effective as medication for major depression and should be first-line for mild-to-moderate symptoms 4
- Other effective modalities: behavioral activation (particularly relevant for anhedonia), interpersonal therapy, problem-solving therapy, brief psychodynamic therapy, mindfulness-based therapy 4
- Therapy should be delivered by licensed mental health professionals using relevant treatment manuals 11
- Include content on cognitive change, behavioral activation, biobehavioral strategies, education, and relaxation strategies 11
- For group therapy options: structured sessions led by licensed professionals covering stress reduction, positive coping, enhancing social support, and health behavior change 11
Family Involvement and Education
- Provide developmentally appropriate psychoeducation to both patient and family about depression causes, symptoms, impairments, and expected treatment outcomes 1
- Educate families about warning signs: new or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe 8
- Discuss limits of confidentiality explicitly—safety concerns override confidentiality 1
- Be aware that family members may have negative reactions (sadness, anger, denial) to the diagnosis 1
- Instruct parents to monitor daily for emergence of agitation, irritability, unusual behavior changes, and suicidality 5
Treatment Goals and Monitoring
- Set specific, measurable treatment goals in key functioning areas: school performance, peer relationships, family interactions, and self-care 1
- Written treatment plans with specific goals improve adherence and outcomes 1
- Monitor for treatment adherence—adolescents with depression often lack motivation to follow through on referrals 11
- If compliance is poor, assess and address obstacles to compliance or discuss alternative interventions 11
Duration of Treatment
- Acute episodes of major depressive disorder require several months or longer of sustained treatment beyond initial response 8
- Continue effective treatment for at least 6-12 months after symptom remission to prevent relapse 8
- Periodically reassess need for maintenance treatment 8
- When discontinuing medication, taper gradually while providing concurrent CBT to decrease relapse risk 7
- Abrupt discontinuation can cause withdrawal symptoms including anxiety, irritability, mood changes, restlessness, sleep changes, headache, sweating, nausea, dizziness, and electric shock-like sensations 8
School Coordination
- Establish partnerships with school personnel to monitor functioning in academic settings 1
- Consider 504 plan or IEP evaluation if depression significantly impacts academic performance 10
- Identify school counselor or trusted adult for check-ins 10
Common Pitfalls to Avoid
- Do not rely on screening scores alone for diagnosis—false-positive rates are 60-76% in primary care settings 4
- Never use "no-suicide contracts"—they are not proven effective and may impair therapeutic alliance 3, 10
- Do not dismiss suicidal statements as attention-seeking or unimportant 2
- Do not overlook comorbid anxiety, which affects treatment selection and outcomes 4
- Do not underestimate the prognostic significance of anhedonia—it predicts poorer recovery and may require dopamine-targeting strategies if SSRI response is inadequate 12, 9
- Do not initiate antidepressants without adequate screening for bipolar disorder risk 5
- For adolescents 18-29 years, be particularly vigilant about increased suicidal behavior risk with SSRIs 13
Follow-Up Schedule
- First follow-up within 48-72 hours of treatment initiation 10
- Weekly visits initially, then biweekly or monthly until symptoms remit 11, 10
- Maintain contact even after referral to mental health specialists—collaborative care results in greater symptom reduction 3
- At each visit: assess treatment adherence, side effects, symptom improvement, functional status, and safety 11